Sanofi’s mRNA Vaccine Gains FDA Fast Track for Chlamydia Prevention

Sanofi has achieved a major milestone in the fight against chlamydia, securing fast track designation from the FDA for its mRNA vaccine candidate. This designation recognizes the urgent need for a preventive solution to address the growing global burden of chlamydia infections, which often go undiagnosed and lead to serious health complications like infertility and pregnancy risks. The vaccine is designed to protect against both initial and repeat infections, with a phase 1/2 clinical trial set to begin shortly in adults aged 18 to 29 years.

Despite the availability of antibiotic treatments, chlamydia rates continue to rise, partly because over 80% of infections are asymptomatic, leading to unintentional transmission. Sanofi’s research is part of the Translational Science Hub, a collaboration with Queensland Government, Griffith University, and the University of Queensland, combining expertise from Australia, France, and the US. Jean-François Toussaint, Global Head of Vaccines R&D at Sanofi, emphasized that this initiative represents a critical step toward making chlamydia a preventable disease through vaccination, addressing a longstanding public health challenge.